QP's platforms and programs support a comprehensive framework for basic research, translational medicine and drug discovery

An Integrated Translational
Platform

ARTERIOME is QP's proprietary end-to-end discovery and translational research platform designed to decipher the regulatory principles governing resistance artery function and dysfunction.
At the core of ARTERIOME is QP's unique in-house bioengineering platform, which enables the harvesting, preservation and multimodal functional analyses of living micro-arteries. This provides the basis for integration of several methodologies and assessments that link microvascular behaviour to underlying molecular mechanisms that can be therapeutically exploited. The platform combines: 
  • Advanced bioengineering
  • Multimodal phenotyping
  • Omic analyses
  • AI-driven target identification
  • Machine learning
  • Clinically relevant disease models
  • Translational research design
1.

Microvascular Perturbation Models

ARTERIOME systematically investigates how disease alters microvascular regulation using clinically relevant perturbation models including heart failure (LAD ligation), subarachnoid hemorrhage, obesity, type 2 diabetes and metabolic syndrome, chronic cardiovascular diseases, inflammatory disorders, and neurovascular diseases. We also incorporate therapeutically-relevant dimensions of circadian regulation and sex differences into our analyses.
2.

Functional and Multi-Omic Microvascular Assessments

A foundational element of ARTERIOME is functional vascular phenotyping in resistance arteries that examine microvascular tone regulation, endothelial function, smooth muscle contractility, and responses to physiological and pharmacological stimuli. These data provide a rich basis for identifying molecular drivers that influence resistance artery function via transcriptomic profiling, proteomic characterization, genetic analyses, advanced computational biology and biomarker discovery.
3.

Vascular Bed-Specific Data Analyses

A hallmark feature of ARTERIOME is that all analyses are performed across multiple vascular beds, recognizing that resistance arteries from the heart, brain, skeletal muscle, kidney, and other organs exhibit distinct regulatory architectures. Exposing distinct microarterial beds to  physiological and pathological conditions, generates comparative data to help identify organ-specific regulatory networks that govern microarterial function.
4.

Microvascular Target Library

The integration of functional and molecular datasets enable sophisticated enrichment analyses that reveal proteins, pathways, and regulatory networks mechanistically linked to microarterial dysfunction. Unlike conventional target discovery approaches that often rely solely on gene expression changes, ARTERIOME prioritizes targets based on demonstrated functional relevance within specific vascular beds and disease contexts. Validated targets are then advanced into QP's proprietary AI-enabled drug discovery pipeline.

Drug Discovery

QP has assembled group of international partners in a Generative-AI Driven Lead Discovery Collaboration to deliver first-in-class microvascular therapies
The drug discovery program is specifically designed to equip machine-learning and AI approaches in drug discovery with QP's detailed molecular insights on microvascular dysfunction to deliver the most promising lead candidates.

QP has partnered with the Zuse Institute Berlin (ZIB), Enamine Ltd., and Proteros who are leaders in advanced computational methods, medicinal chemistry, and structural biology.  The collaboration spans early generative molecular design and docking studies with the ZIB developing its proprietary algorithms, via the REAL®-directed compound synthesis by Enamine, the world’s largest supplier of make-on-demand small molecules, to the validation of hit compounds by Proteros using their structure-based drug discovery platform.

GENESiS PROGRAM
_
Zuse Institute Berlin
The Zuse-Institute Berlin (ZIB) is an interdisciplinary research institute for applied mathematics and data-intensive high-performance computing. Its research focuses on modeling, simulation and optimization with scientific cooperation partners from academia and industry.
_
Proteros biostructures
Proteros is a Munich-based provider of structure-based early stage drug discovery services with a cutting-edge discovery engine tailored to unlock even the most technically challenging drug targets.
_
Enamine Ltd.
Enamine is a scientifically driven, integrated discovery CRO with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.7 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery.

Clinical Ecosystem

QP is embedded in a world-leading clinical research environment anchored in Toronto and supported by international partners.
QP's primary research partnership with the Toronto Centre for Microvascular Medicine (TCMM) is strategically positioned to support the seamless progression of therapeutic targets generated from Arteriome into its Drug Discovery program, nonclinical validation studies and finally clinical testing. By focussing its discovery research efforts within the Toronto university-hospital innovation ecosystem, QP's clinical programs benefit from:
  • High-quality clinical research centers for proof-of-concept studies linking microvascular mechanisms to human clinical endpoints
  • Integration of Key Opinion Leaders in study design to ensure clinical relevance, reflecting key patient outcomes and medical needs
  • Driving clinical data generation on microvascular dysfunction and novel biomarker research
In doing so, QP is championing a unique partnership model designed to combine scientific depth with translational agility.
SEE OUR CURRENT TRIAL
  • University of Toronto
  • Centre for Microvascular Medicine
  • Ted Rogers Centre for Heart Research
  • St. Michael's Hospital, Unity Health
  • SPHERE, Unity Health
  • University Health Network (UHN)

Research at QP is made possible through a dynamic network of private investors, academic collaborators, and support from regulatory bodies in the public sector.

Contact Us
Menu
AboutScienceR&DLYRICGENESiSTeam
© Qanatpharma 2026. ALL RIGHTS RESERVED.
ImprintPrivacy PolicyOpen Preferences